MND Treatment Advances: Bringing Care Home for Patients
For individuals battling motor neurone disease (MND), also known as Amyotrophic Lateral Sclerosis (ALS), a new era of care is dawning. Recent advancements are shifting treatment paradigms, offering a lifeline that reduces the burden of frequent hospital visits and prioritizes quality of life. A key development is the increasing accessibility of Radicava (edaravone), a treatment listed on the Pharmaceutical Benefits Scheme (PBS) since May 2025 and its delivery through innovative hospital-in-the-home services like Epworth at Home.
Radicava: A New Hope for Slowing Progression
Radicava is an intravenous infusion designed to slow the progression of ALS, the most common form of MND. It’s administered by healthcare professionals, and its effectiveness hinges on early intervention – ideally within two years of symptom onset. The treatment protocol involves a rigorous initial phase, with daily infusions for 14 consecutive days in the first month. This then transitions to 10 infusions over a 14-day period, followed by a 14-day break.
The Rise of Hospital-in-the-Home Services
Traditionally, Radicava treatment required daily hospital visits, a significant challenge for patients already facing the debilitating effects of MND. Services like Epworth at Home are changing this, bringing the treatment directly to patients’ homes. After initial hospital-based doses for the first and second cycles, eligible patients can receive subsequent infusions from highly trained nurses in the comfort of their own homes.
“MND impacts daily functions like speech, swallowing, walking and fine motor skills, and it can also impact breathing,” explains Cindy Joffe, Epworth at Home Director. “Our goal is to ensure patients can receive this new treatment in the comfort of their home – reducing the need to visit the hospital every day.”
Why Early Diagnosis is Crucial
The effectiveness of Radicava underscores the importance of early and accurate diagnosis. MND can be difficult to diagnose, but prompt detection is vital, as treatment must begin within two years of diagnosis to be most effective. Nadine Fraginal, Epworth Nurse Unit Manager, emphasizes this point: “MND is difficult to diagnose, and early detection is key as treatment needs to commence within 2 years of diagnosis. This is why our team is so committed to delivering this therapy promptly and compassionately.”
Future Trends in MND Care: What to Expect
The shift towards at-home treatment represents a broader trend in healthcare: a move towards patient-centered, accessible care. Several factors suggest this trend will accelerate in the coming years.
- Telemedicine Integration: Remote monitoring and virtual consultations will likely grow more integrated into MND care, allowing for more frequent check-ins and personalized treatment adjustments.
- Personalized Medicine: As our understanding of the genetic and biological factors contributing to MND grows, treatments will become increasingly tailored to individual patients.
- AI-Powered Diagnostics: Artificial intelligence may play a role in earlier and more accurate diagnosis, potentially identifying subtle patterns in patient data that might otherwise be missed.
- Expanded Access to At-Home Care: More hospitals and healthcare providers are expected to adopt hospital-in-the-home models, making treatment more convenient and accessible for patients with MND and other chronic conditions.
Did you know?
Radicava is the first new PBS-listed treatment for ALS in over 20 years, marking a significant step forward in MND care.
Frequently Asked Questions
- What is Radicava used for? Radicava (edaravone) is used to slow the progression of Amyotrophic Lateral Sclerosis (ALS), the most common form of MND.
- How is Radicava administered? It is administered as an intravenous infusion, initially daily for 14 days, then transitioning to a cyclical pattern of infusions and breaks.
- What is Epworth at Home? Epworth at Home is a hospital-in-the-home service that allows eligible patients to receive Radicava infusions in the comfort of their own homes.
- Why is early diagnosis critical? Treatment with Radicava is most effective when started within two years of symptom onset.
The advancements in MND treatment, coupled with innovative care delivery models, offer a beacon of hope for individuals and families affected by this devastating disease. Continued research and a commitment to patient-centered care will be crucial in shaping a brighter future for those living with MND.
Learn more about accessing support services for MND: MND Australia
